Kidney Cancer

An expert explained what aspects of a patient’s disease cancer care teams use to determine the best treatment options for patients with clear cell renal cell carcinoma.

Patients with BAP1-mutated renal cell carcinoma who were treated with Lynparza obtained responses with favorable side effect profiles.

A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.

Adolescents and young adults undergoing VEGF treatment for nonmetastatic, high-risk renal cell carcinoma may still experience heart-related conditions like left ventricular systolic dysfunction and high blood pressure.

The addition of Tecentriq to Cabometyx did not improve the length of time patients lived without their disease getting worse for individuals with previously treated advanced kidney cancer, and came with additional side effects, too, recent research showed.

Adding Cabometyx to Opdivo and Yervoy tended to improve progression-free survival in patients with advanced kidney cancer, research showed.

After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.

Cabometyx, Opdivo and Yervoy led to high disease control rates across different subgroups of patients with kidney cancer, research showed.

Nearly three-fourths of patients with clear cell renal cell carcinoma had a disease response lasting 12 months or longer after being treated with Welireg and Lenvima, study data showed.

Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.

Cabometyx plus Tecentriq failed to improve progression-free survival in patients with kidney cancer.

The drug duo Lenvina plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, extended follow-up of the CLEAR trial showed.

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.

Discovering different genetic mutations to target ... continues to add to the excitement.

Going through cancer is a marathon, not a sprint.

As a part of its “Speaking Out” video series, CURE® spoke with Meryl Uranga, on behalf of KidneyCAN, about the importance of working as a team with their clinicians and getting educated before making decisions.

One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.

FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.

HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease.

Take a look at the top advancements and most popular articles about kidney cancer from the year 2022.

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

Newer drugs for kidney cancer have proven extremely effective but can cause unwanted symptoms that affect safety and quality of life.

A kidney cancer diagnosis may negatively affect a patient’s mental health; however, exercise may help put them at ease.

I was misdiagnosed twice before receiving my kidney cancer diagnosis, and along the way, I learned the importance of expert doctors and clinical trials.

Once seen as a malignancy resistant to typical treatments such as chemotherapy, metastatic kidney cancer has come a long way in the past 20 years.

Twenty years of FDA approvals for the treatment of metastatic kidney cancer have allowed patients to live longer.

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.

Although patients treated with the combination did not have significant improvements in survival, telaglenastat and Cabometyx did not increase the rate of side effects in patients.

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.